Sophie Laurent
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sophie Laurent has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
L. Vander Elst
6 shared publicationsR N Muller
3 shared publicationsR.N. Muller
3 shared publicationsL Vander Elst
2 shared publicationsR. N. Muller
Department of Organic and Biomedical Chemistry, NMR and Molecular Imaging Laboratory, University of Mons‐Hainaut, Mons, Belgium
2 shared publicationsS. Boutry
2 shared publications
Latest Publications
- 1 January 2018
- Published by Elsevier
List of Contributors
- 1 March 2011
- Published by Elsevier in Journal of Magnetism and Magnetic Materials
- Vol. 323 (5) , 410-415
An original route to stabilize and functionalize magnetite nanoparticles for theranosis applications
- 1 March 2011
- Published by Elsevier in Journal of Magnetism and Magnetic Materials
- Vol. 323 (5) , 410-415
An original route to stabilize and functionalize magnetite nanoparticles for theranosis applications
- 1 March 2010
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 94, S28-S29
71 poster: Iron Oxide Particles Covered with Hexapeptides Targeted at Phosphatidylserine as MR Biomarkers of Tumor Cell Death
- 1 March 2010
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 94, S28-S29
71 poster: Iron Oxide Particles Covered with Hexapeptides Targeted at Phosphatidylserine as MR Biomarkers of Tumor Cell Death
- 1 December 2009
- Vol. 53 (6) , 586-603
Lanthanide complexes for magnetic resonance and optical molecular imaging.
Lanthanide complexes are more and more used in biomedical imaging as contrast agents (CA). The development of these paramagnetic complexes as CA for medical magnetic resonance imaging (MRI) and luminescent probes for optical imaging is very complementary. Gd complexes are well known as CA for MRI and Eu/Tb complexes are often used in microscopy or fluorescence imaging. Each imaging technique has its limitation: low sensitivity but high spatial resolution for MRI and limited penetration but high sensitivity for optical imaging. A bimodal agent can be used for these two methods and give more informations, they can be visualized simultaneously by light and MR imaging. Such compounds are based on the coordination chemistry of the lanthanide ions with an organic ligand to form a stable complex and on the properties of the lanthanide ions. Gd complexes with a chromophore allows also the luminescent detection. This review describes the properties of the lanthanide ions and of their complexes and gives some typical applications of the complexes. The luminescence properties show high quantum yield and long luminescence lifetimes. The relaxometric data of the Gd complexes are comparable or higher than commercial and clinically Gd-DTPA derivatives.
- 1 December 2009
- Vol. 53 (6) , 586-603
Lanthanide complexes for magnetic resonance and optical molecular imaging.
Lanthanide complexes are more and more used in biomedical imaging as contrast agents (CA). The development of these paramagnetic complexes as CA for medical magnetic resonance imaging (MRI) and luminescent probes for optical imaging is very complementary. Gd complexes are well known as CA for MRI and Eu/Tb complexes are often used in microscopy or fluorescence imaging. Each imaging technique has its limitation: low sensitivity but high spatial resolution for MRI and limited penetration but high sensitivity for optical imaging. A bimodal agent can be used for these two methods and give more informations, they can be visualized simultaneously by light and MR imaging. Such compounds are based on the coordination chemistry of the lanthanide ions with an organic ligand to form a stable complex and on the properties of the lanthanide ions. Gd complexes with a chromophore allows also the luminescent detection. This review describes the properties of the lanthanide ions and of their complexes and gives some typical applications of the complexes. The luminescence properties show high quantum yield and long luminescence lifetimes. The relaxometric data of the Gd complexes are comparable or higher than commercial and clinically Gd-DTPA derivatives.
- 1 January 2008
- Published by Springer Nature
- p. 135-165
Contrast Agents: Magnetic Resonance
Even though the intrinsic magnetic resonance imaging (MRI) contrast is much more flexible than in other clinical imaging techniques, the diagnosis of several pathologies requires the involvement of contrast agents (CAs) that can enhance the difference between normal and diseased tissues by modifying their intrinsic parameters. MR CAs are indirect agents because they do not become visible by themselves as opposed to other imaging modalities. The signal enhancement produced by MRI CAs (i.e., the efficiency of the CAs) depends on their longitudinal (r1) and transverse (r2) relaxivity (expressed in s−1 mmol−1 1), which is defined as the increase of the nuclear relaxation rate (the reciprocal of the relaxation time) of water protons produced by 1 mmol per liter of CA. Paramagnetic CAs (most of them complexes of gadolinium) are frequently used in clinics as extracellular, hepatobiliary or blood pool agents. Low molecular weight paramagnetic CAs have similar effects on R1 and R2, but the predominant effect at low doses is that of T1 shortening (and R1 enhancement). Thus, organs taking up such agents will become bright in a T1-weighted MRI sequence; these CAs are thus called positive contrast media. The CAs known as negative agents influence signal intensity mainly by shortening T2* and T2, which produces the darkening of the contrast-enhanced tissue. These CAs are generally composed of superparamagnetic nanoparticles, consisting of iron oxides (magnetite, Fe3O4, maghemite, γFe2O3, or other ferrites). Iron oxide nanoparticles are taken up by the monocyte-macrophage system, which explains their potential application as MRI markers of inflammatory and degenerative disorders. Most of the contemporary MRI CAs approved for clinical applications are non-specific for a particular pathology and report exclusively on the anatomy and the physiological status of various organs. A new generation of MRI CAs is progressively emerging in the current context of molecular imaging, agents that are designed to detect with a high specificity the cellular and molecular hallmarks of various pathologies.
- 1 January 2008
- Published by Springer Nature
- p. 135-165
Contrast Agents: Magnetic Resonance
Even though the intrinsic magnetic resonance imaging (MRI) contrast is much more flexible than in other clinical imaging techniques, the diagnosis of several pathologies requires the involvement of contrast agents (CAs) that can enhance the difference between normal and diseased tissues by modifying their intrinsic parameters. MR CAs are indirect agents because they do not become visible by themselves as opposed to other imaging modalities. The signal enhancement produced by MRI CAs (i.e., the efficiency of the CAs) depends on their longitudinal (r1) and transverse (r2) relaxivity (expressed in s−1 mmol−1 1), which is defined as the increase of the nuclear relaxation rate (the reciprocal of the relaxation time) of water protons produced by 1 mmol per liter of CA. Paramagnetic CAs (most of them complexes of gadolinium) are frequently used in clinics as extracellular, hepatobiliary or blood pool agents. Low molecular weight paramagnetic CAs have similar effects on R1 and R2, but the predominant effect at low doses is that of T1 shortening (and R1 enhancement). Thus, organs taking up such agents will become bright in a T1-weighted MRI sequence; these CAs are thus called positive contrast media. The CAs known as negative agents influence signal intensity mainly by shortening T2* and T2, which produces the darkening of the contrast-enhanced tissue. These CAs are generally composed of superparamagnetic nanoparticles, consisting of iron oxides (magnetite, Fe3O4, maghemite, γFe2O3, or other ferrites). Iron oxide nanoparticles are taken up by the monocyte-macrophage system, which explains their potential application as MRI markers of inflammatory and degenerative disorders. Most of the contemporary MRI CAs approved for clinical applications are non-specific for a particular pathology and report exclusively on the anatomy and the physiological status of various organs. A new generation of MRI CAs is progressively emerging in the current context of molecular imaging, agents that are designed to detect with a high specificity the cellular and molecular hallmarks of various pathologies.
- 1 November 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (22) , 6230-6233
In vitro characterization of the Gd complex of [2,6-pyridinediylbis(methylene nitrilo)] tetraacetic acid (PMN-tetraacetic acid) and of its Eu analogue, suitable bimodal contrast agents for MRI and optical imaging
- 1 November 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (22) , 6230-6233
In vitro characterization of the Gd complex of [2,6-pyridinediylbis(methylene nitrilo)] tetraacetic acid (PMN-tetraacetic acid) and of its Eu analogue, suitable bimodal contrast agents for MRI and optical imaging
- 1 March 2006
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 1 (2) , 84
CMR 2005: 12.04: Stealthy magnetophages, a new tool for molecular imaging
- 1 March 2006
- Published by Wiley in Contrast Media & Molecular Imaging
- Vol. 1 (2) , 84
CMR 2005: 12.04: Stealthy magnetophages, a new tool for molecular imaging
- 1 June 2001
- Published by Springer Nature in Magnetic Resonance Materials in Physics, Biology and Medicine
- Vol. 12 (2-3) , 92-95
Deuterium NMR study of the MP-2269: albumin interaction — a step forward to the dynamics of non-covalent binding
MP-2269, the Gd(III) complex of 4-pcntylbicyclo[2.2.2] octane-l-carboxyl-di-L-aspartyl-lysinc-derived-DTPA, is a small Gd-agent that binds non-covalently to scrum albumin in vivo to assume the enhanced relaxivities associated with macromolecular agents, (due in part to increased rotational correlation time, τR). To further explore the fundamental parameters that govern the dynamics of water proton relaxation enhancement by this prototypical albumin-binding agent, the rotational correlation time (τR) for the deuterated La(III) analog of MP-2269 has been independently measured in the presence and absence of 4% albumin using2H-NMR approaches. The diamagnetic La(III) analog of MP-2269 was deuterated at the α-position of the carbonyl groups.2H-NMR studies were conducted at 7.05T (46 MHz) and 310°K on a Bruker NMR spectrometer. Spectral deconvolution permitted calculation of transverse relaxation rates, 1/T2, from the NMR linewidths and subsequently, τR. The results yielded a τR of the albumin bound complex of ∼ 8 ns. This value is intermediate between those earlier estimated by17O-NMR (∼ 1 ns) and1H-NMRD (∼ 20–50 ns) and significantly shorter than that of albumin. The2H-NMR study results also indicate that the exchange between free and albumin-bound forms of the La(III) analog is slow (exchange lifetimes > 1 ms). This slow exchange does not affect the water residence lifetimes (τM 140-280 ns).
- 1 June 2001
- Published by Springer Nature in Magnetic Resonance Materials in Physics, Biology and Medicine
- Vol. 12 (2-3) , 92-95
Deuterium NMR study of the MP-2269: albumin interaction — a step forward to the dynamics of non-covalent binding
MP-2269, the Gd(III) complex of 4-pcntylbicyclo[2.2.2] octane-l-carboxyl-di-L-aspartyl-lysinc-derived-DTPA, is a small Gd-agent that binds non-covalently to scrum albumin in vivo to assume the enhanced relaxivities associated with macromolecular agents, (due in part to increased rotational correlation time, τR). To further explore the fundamental parameters that govern the dynamics of water proton relaxation enhancement by this prototypical albumin-binding agent, the rotational correlation time (τR) for the deuterated La(III) analog of MP-2269 has been independently measured in the presence and absence of 4% albumin using2H-NMR approaches. The diamagnetic La(III) analog of MP-2269 was deuterated at the α-position of the carbonyl groups.2H-NMR studies were conducted at 7.05T (46 MHz) and 310°K on a Bruker NMR spectrometer. Spectral deconvolution permitted calculation of transverse relaxation rates, 1/T2, from the NMR linewidths and subsequently, τR. The results yielded a τR of the albumin bound complex of ∼ 8 ns. This value is intermediate between those earlier estimated by17O-NMR (∼ 1 ns) and1H-NMRD (∼ 20–50 ns) and significantly shorter than that of albumin. The2H-NMR study results also indicate that the exchange between free and albumin-bound forms of the La(III) analog is slow (exchange lifetimes > 1 ms). This slow exchange does not affect the water residence lifetimes (τM 140-280 ns).
- 1 January 1997
- Vol. 412, 135-8
Multinuclear MR characterization of a new hepatobiliary contrast agent. Preliminary results.
The aim of this work was to characterize the hepatobiliary contrast agent Gd-EOB-DTPA in various media: water solution, protein solution, phosphorylated metabolite solution, and excised and perfused liver tissue. Different NMR techniques were used: analyses of H-1 NMRD profiles, H-2 NMR relaxation rates, O-17 relaxation rates and chemical shifts, and P-31 relaxation rates and peak area. The higher proton relaxivity of Gd-EOB-DTPA in water as compared to that of Gd-DTPA is due to a smaller distance r and to a longer tau R. The kinetic stability of the former compound in ATP solution is higher and it forms noncovalent bonds with human serum albumin. Internalization of the contrast agent by the hepatocytes does not impair the ATP metabolism of the cells but induces relaxation effects on the intracellular metabolites of the liver. Multinuclear MR studies allow the extensive characterization of MR contrast agents in in-vitro and ex-vivo model systems.
- 1 January 1997
- Vol. 412, 135-8
Multinuclear MR characterization of a new hepatobiliary contrast agent. Preliminary results.
The aim of this work was to characterize the hepatobiliary contrast agent Gd-EOB-DTPA in various media: water solution, protein solution, phosphorylated metabolite solution, and excised and perfused liver tissue. Different NMR techniques were used: analyses of H-1 NMRD profiles, H-2 NMR relaxation rates, O-17 relaxation rates and chemical shifts, and P-31 relaxation rates and peak area. The higher proton relaxivity of Gd-EOB-DTPA in water as compared to that of Gd-DTPA is due to a smaller distance r and to a longer tau R. The kinetic stability of the former compound in ATP solution is higher and it forms noncovalent bonds with human serum albumin. Internalization of the contrast agent by the hepatocytes does not impair the ATP metabolism of the cells but induces relaxation effects on the intracellular metabolites of the liver. Multinuclear MR studies allow the extensive characterization of MR contrast agents in in-vitro and ex-vivo model systems.